Clinical Utility of Comprehensive Genomic Profiling in Patients with Unresectable Hepatocellular Carcinoma
Authors:
- Shun IshidoSIShun Ishido
- Kaoru TsuchiyaKTKaoru Tsuchiya
- Yoshihito KanoYKYoshihito Kano
- Yutaka YasuiYYYutaka Yasui
- Kenta TakauraKTKenta Takaura
- Naoki UchiharaNUNaoki Uchihara
- Keito SuzukiKSKeito Suzuki
- Yuki TanakaYTYuki Tanaka
- Haruka MiyamotoHMHaruka Miyamoto
- Michiko YamadaMYMichiko Yamada
- Hiroaki MatsumotoHMHiroaki Matsumoto
- Tsubasa NobusawaTNTsubasa Nobusawa
Open Access
Abstract
This study aimed to investigate the clinical usefulness of comprehensive genomic profiling (CGP) in patients with unresectable hepatocellular carcinoma who received multiple systemic therapies in real-world practice. In this study, all nine patients had gene alterations, and seven were candidates eligible for clinical trials based on the results of CGP. The median number of alterations per patient was four, and the blood sample was used in five patients with extrahepatic metastasis. We revealed the genomic information of the patients who received multiple systemic therapies and reported the utility of blood samples in patients with extrahepatic metastasis. Furthermore, the genomic status in patients treated with multiple molecular-targeted agents, including checkpoint inhibitors, would contribute to developing newer systemic agents. The molecular mechanism of hepatocellular carcinoma (HCC) is partially demonstrated. Moreover, in the patients receiving multiple molecular-targeted therapies, the gene alternations are still unknown. Six molecular-targeted therapies of unresectable HCC (uHCC) and comprehensive genomic profiling (CGP) have been approved in clinical practice. Hence, the utility of CGP in patients with uHCC treated with multiple molecular-targeted agents is investigated. The data of the patients with uHCC who received CGP tests were collected, retrospectively, between February 2021 and May 2022. Gene alterations detected by foundation testing, excluding variants of unknown significance, were reported in all nine patients. The samples for CGP were derived from liver tumor biopsy (n = 2), surgical specimens of bone metastases (n = 2), and blood (n = 5). The median number of systemic therapies was four. Seven patients were candidates eligible for clinical trials. One patient with a high tumor mutation burden (TMB) could receive pembrolizumab after CGP. This study presented genomic alternations after receiving multiple molecular-targeted therapies. However, further investigation needs to be conducted to develop personalized therapies and invent newer agents for treating HCC.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP20fk0210067h0001)
This publication has 24 references indexed in Scilit:
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialThe Lancet, 2018
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2017
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of SorafenibJAMA, 2014
- Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-AnalysisPLOS ONE, 2014
- Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trendsJournal of Hepatology, 2014
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNature Biotechnology, 2013
- Phase 1/2 study of everolimus in advanced hepatocellular carcinomaCancer, 2011
- Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP‐9Hepatology Research, 2009
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008